Javascript must be enabled to continue!
Potential drug–drug interactions and associated factors among hospitalized cardiac patients at Jimma University Medical Center, Southwest Ethiopia
View through CrossRef
Background: Concomitant use of several drugs for a patient is often imposing increased risk of drug–drug interactions. Drug–drug interactions are a major cause for concern in patients with cardiovascular disorders due to multiple co-existing conditions and the wide class of drugs they receive. This study is aimed to assess the prevalence of potential drug–drug interactions and associated factors among hospitalized cardiac patients at medical wards of Jimma University Medical Center, Southwest Ethiopia. Methods: A hospital-based prospective observational study was conducted among hospitalized cardiac adult patients based on the inclusion criteria. Patient-specific data were collected using structured data collection tool. Potential drug–drug interaction was analyzed using Micromedex 3.0 DRUG-REAX® System. Data were analyzed using statistical software package, version 20.0. To identify the independent predictors of potential drug–drug interaction, multiple stepwise backward logistic regression analysis was done. Statistical significance was considered at a p-value < 0.05. Written informed consent from patients was obtained and the patients were informed about confidentiality of the information obtained. Results: Of the total 200 patients, majority were male (52.50%) and with a mean(±standard deviation) age of 42.54(±7.89) years. Out of 673 patients’ prescriptions analyzed, 521 prescriptions comprised potential drug interactions and it was found that 967 drug interactions were present. The prevalence rate of potential drug–drug interactions among the study unit was 4.83 per patient and 1.44 per prescription regardless of the severity during their hospital stay. Overall the prevalence rate of potential drug interactions was 74.41%. Older age (adjusted odds ratio (95% confidence interval): 1.067 (2.33–27.12), p = 0.049), long hospital stay (⩾7 days) (adjusted odds ratio (95% confidence interval): 2.80 (1.71–4.61), p = 0.024), and polypharmacy (adjusted odds ratio (95% confidence interval): 1.64 (0.66–4.11), p = 0.041) were independent predictors for the occurrence of potential drug–drug interactions. Conclusion: This study demonstrated a high prevalence of potential DIs among hospitalized cardiac patients in medical wards due to the complexity of pharmacotherapy. The prevalence rate is directly related to age, number of prescribed drugs, and length of hospital stay. Pharmacodynamic drug–drug interaction was the common mechanism of drug–drug interactions. Therefore, close monitoring of hospitalized patients is highly recommended.
SAGE Publications
Title: Potential drug–drug interactions and associated factors among hospitalized cardiac patients at Jimma University Medical Center, Southwest Ethiopia
Description:
Background: Concomitant use of several drugs for a patient is often imposing increased risk of drug–drug interactions.
Drug–drug interactions are a major cause for concern in patients with cardiovascular disorders due to multiple co-existing conditions and the wide class of drugs they receive.
This study is aimed to assess the prevalence of potential drug–drug interactions and associated factors among hospitalized cardiac patients at medical wards of Jimma University Medical Center, Southwest Ethiopia.
Methods: A hospital-based prospective observational study was conducted among hospitalized cardiac adult patients based on the inclusion criteria.
Patient-specific data were collected using structured data collection tool.
Potential drug–drug interaction was analyzed using Micromedex 3.
0 DRUG-REAX® System.
Data were analyzed using statistical software package, version 20.
To identify the independent predictors of potential drug–drug interaction, multiple stepwise backward logistic regression analysis was done.
Statistical significance was considered at a p-value < 0.
05.
Written informed consent from patients was obtained and the patients were informed about confidentiality of the information obtained.
Results: Of the total 200 patients, majority were male (52.
50%) and with a mean(±standard deviation) age of 42.
54(±7.
89) years.
Out of 673 patients’ prescriptions analyzed, 521 prescriptions comprised potential drug interactions and it was found that 967 drug interactions were present.
The prevalence rate of potential drug–drug interactions among the study unit was 4.
83 per patient and 1.
44 per prescription regardless of the severity during their hospital stay.
Overall the prevalence rate of potential drug interactions was 74.
41%.
Older age (adjusted odds ratio (95% confidence interval): 1.
067 (2.
33–27.
12), p = 0.
049), long hospital stay (⩾7 days) (adjusted odds ratio (95% confidence interval): 2.
80 (1.
71–4.
61), p = 0.
024), and polypharmacy (adjusted odds ratio (95% confidence interval): 1.
64 (0.
66–4.
11), p = 0.
041) were independent predictors for the occurrence of potential drug–drug interactions.
Conclusion: This study demonstrated a high prevalence of potential DIs among hospitalized cardiac patients in medical wards due to the complexity of pharmacotherapy.
The prevalence rate is directly related to age, number of prescribed drugs, and length of hospital stay.
Pharmacodynamic drug–drug interaction was the common mechanism of drug–drug interactions.
Therefore, close monitoring of hospitalized patients is highly recommended.
Related Results
Diplomatic Claims (Eritrea v. Ethiopia), Eritrea ' s Claim 20/Ethiopia ' s Claim 8, Partial Awards; Economic Loss Throughout Ethiopia (Ethiopia v. Eritrea), Ethiopia ' s Claim 7, Partial Award; Jus ad Bellum (Ethiopia v. Eritrea), Ethiopia ' s Claims 1-8,
Diplomatic Claims (Eritrea v. Ethiopia), Eritrea ' s Claim 20/Ethiopia ' s Claim 8, Partial Awards; Economic Loss Throughout Ethiopia (Ethiopia v. Eritrea), Ethiopia ' s Claim 7, Partial Award; Jus ad Bellum (Ethiopia v. Eritrea), Ethiopia ' s Claims 1-8,
Diplomatic Claims (Eritrea v. Ethiopia), Eritrea's Claim 20/Ethiopia's Claim 8, Partial Awards. At <http://www.pca-cpa.org>.Eritrea Ethiopia Claims Commission, December 19, 2...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Cardiac Myxoma Post-Transseptal Ablation: Coincidence or Causation?
Cardiac Myxoma Post-Transseptal Ablation: Coincidence or Causation?
Background: Cardiac myxomas are benign cardiac neoplasms usually found solitarily located within a single cardiac chamber, most commonly in the left atrium. With no established cau...
T211. COMPARISON OF REHOSPITALIZATION RATE IN INDIVIDUALS WITH SCHIZOPHRENIA CHANGED FROM PALIPERIDONE PALMITATE TO ORAL ANTIPSYCHOTICS
T211. COMPARISON OF REHOSPITALIZATION RATE IN INDIVIDUALS WITH SCHIZOPHRENIA CHANGED FROM PALIPERIDONE PALMITATE TO ORAL ANTIPSYCHOTICS
Abstract
Background
Long-acting antipsychotic therapy (LAT) may help effectively manage individuals with schizophrenia by optimi...
Incidence and predictors of delirium among the intensive care unit patients at Jimma Medical Center, Southwest Ethiopia
Incidence and predictors of delirium among the intensive care unit patients at Jimma Medical Center, Southwest Ethiopia
Objective: Delirium is characterized by impaired attention and awareness, accompanied by cognitive deficits. It develops rapidly and poses a considerable burden on healthcare sy...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Jimma Town: Foundation and Early Growth from ca. 1830 to 1936
Jimma Town: Foundation and Early Growth from ca. 1830 to 1936
Abstract
This study deals with the early history of Jimma town and its growth from its foundation until 1936. It explores social, economic and administrative them...

